Bishal Gyawali: Very productive meeting of the MCBS working group

Bishal Gyawali shared on X:               .

“We had a very productive meeting of the ESMO Magnitude of Clinical Benefit Scale (MCBS) working group.

Several updates are coming up and we are working hard to keep MCBS as the most scientific and reliable tool to measure the value of new cancer drugs.

Proud of our team. Stay tuned for updates!”

Source: Bishal Gyawali/X

Bishal Gyawali, MD, PhD, is a medical oncologist from Nepal. Currently an Associate Professor at Queen’s University, Kingston, Canada, and affiliated with Brigham and Women’s Hospital, Boston, USA, he is involved in global oncology initiatives.

Dr. Gyawali serves on several committees, including the WHO Essential Medicines List Cancer Medicines Working Group and ASCO’s Health Equity and Outcomes Committee, contributing significantly to cancer policy and evidence-based oncology.